HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 1.25 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
NA | Ponatinib | Iclusig | 15 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
NA | Sunitinib malate | Sutent | 37.5 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
NA | Tepotinib Hydrochloride | Tepmetko | 225mg | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Yes | 2021 | In Use | |||
NA | Tazemetostat | Tazverik | 200mg | Chemotherapy | Enzyme Inhibitor | EZH2 | Yes | 2020 | In Use | |||
NA | Sunitinib malate | Sutent | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
NA | Abiraterone acetate | Zytiga | 250 mg | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Yes | 2011 | In Use | |||
NA | Palbociclib | Ibrance | 75 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2015 | In Use | |||
NA | Bromocriptine Mesylate | Parlodel | Chemotherapy | Dopamine Agonist | Ergot Derivative | Yes | 1978 | In Use | ||||
Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
NA | Bexarotene | Targretin | 75mg | Chemotherapy | Immunomodulator | Retinoic Acid Derivative | Yes | 2014 | In Use | |||
NA | Cabozantinib | Cabometyx | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
NA | Selinexor | Xpovio | 20mg, 40mg, 50mg, 60mg | Chemotherapy | Enzyme Inhibitor | XPO1 | Yes | 2019 | In Use | |||
NA | Aprepitant | Emend | 125 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
NA | Bicalutamide | Casodex | 50 mg | Hormonal Therapy | Androgen Receptor Inhibitor | non-steriodal | Yes | 1995 | In Use | |||
NA | Raloxifene Hydrochloride | Evista | 60 mg | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Yes | 1997 | In Use | ||||
NA | Avapritinib | Ayvakit | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
NA | Thalidomide | Thalomid | 50 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
NA | Uridine Triacetate | Xuriden | 2 g | Ancillary Therapy | Chemoprotective | Antidote | Yes | 2015 | In Use | |||
NA | Testolactone | Teslac | 250 mg | Hormonal Therapy | Androgen | Yes | 1970 | Jun 25, 2005 | No Longer Used | |||
Futibatinib | Lytgobi | 4mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Yes | 2023 | In Use | ||||
J8705 | Topotecan | Hycamtin | 0.25 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | Yes | 1996 | Jan 1, 2009 | In Use | ||
NA | Methyltestosterone | Android, Methitest, Testred | 10 mg | Hormonal Therapy | Androgen | Yes | 1982 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.